07 September 2022
: Case report 
A Case of Segmental Arterial Mediolysis of Multiple Visceral Arteries Following Anti-COVID-19 Vaccination: Late Complication or Rare Coincidence?
Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Management of emergency care, Unexpected drug reaction, Clinical situation which can not be reproduced for ethical reasons
Akihiro Takeda1ABCDEF*, Wataru Koike2BCD, Fumihiro Okumura3BCDDOI: 10.12659/AJCR.937505
Am J Case Rep 2022; 23:e937505
Table 2. Vasculitis, thrombosis, and collagen disease screen.
| Laboratory tests (reference range) | Results |
|---|---|
| Rheumatoid factor (0–15.0 IU/mL) | 2.0 IU/mL |
| IgA (93–393 mg/dL) | 76 mg/dL (↓) |
| IgM (33–183 mg/dL) | 105 mg/dL |
| IgG (861–1747 mg/dL) | 867 mg/dL |
| C3 (73–138 mg/dL) | 113 mg/dL |
| C4 (11–31 mg/dL) | 28.5 mg/dL |
| PT/INR (0.99) | 0.85–1.15 |
| APTT (30.4 s) | 24.0–34.0 s |
| Fibrinogen (200–400 mg/dL) | 467 mg/dL (↑) |
| Fibrinogen degradation products (−5.0 μg/mL) | 2.3 μg/mL |
| D-dimer (−1.0 μg/mL) | 1.1 μg/mL (↑) |
| Antithrombin 3 (80–130%) | 92% |
| Antinuclear antibody (0–40) | 0–40 |
| Anti-cardiolipin antibody (−10 U/mL) | 3 U/mL |
| PR3-ANCA (0–2.0 IU/mL) | 0.8 IU/mL |
| MPO-ANCA (0–3.5 IU/mL) | 0.7 IU/mL |
| CH50 (30–45 U/mL) | 53 U/mL (↑) |
| Protein C (70–140%) | 100% |
| Protein S (63.5–149.0%) | 79.8% |
| Anti-CCP antibody (0–4.5 U/mL) | 0.5 U/mL |
| IgG4 (11–121 mg/dL) | 23 mg/dL |
| (↑): higher than normal value; (↓) lower than normal value. | |